Vascular smooth muscle cells from hypertensive patient-derived induced pluripotent stem cells to advance hypertension pharmacogenomics

Stem Cells Translational Medicine

Volumn 4, Issue 12, 2015, Pages 1380-1390

  Biel, Nikolett M ^a,b   Santostefano, Katherine E ^a,b   Divita, Bayli B ^a,b   El Rouby, Nihal ^c   Carrasquilla, Santiago D ^d   Simmons, Chelsey ^e,f   Nakanishi, Mahito ^g   Cooper DeHoff, Rhonda M ^c,f   Johnson, Julie A ^c,f   Terada, Naohiro ^a,b  

^a and Laboratory Medicine   (United States)

^b College of Pharmacy and Center for Pharmacogenomics ^*  (United States)

^c Department of Pharmacotherapy and Translational Research   (United States)

^d University of Florida   (United States)

^e Department of Chemical Engineering and Materials Science   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

Hypertension; Induced pluripotent stem cells; Personalized medicine; Vascular smooth muscle cells

Indexed keywords

BIOLOGICAL MARKER; ENDOTHELIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ADULT; AGED; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINE; CELL SELECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENOMICS; PLURIPOTENT STEM CELL; SINGLE NUCLEOTIDE POLYMORPHISM; TRACTION FORCE MICROSCOPY; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MOUSE; PATHOLOGY; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; HUMANS; HYPERTENSION; INDUCED PLURIPOTENT STEM CELLS; MALE; MICE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE;

EID: 84949655013     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0126     Document Type: Article

References (44)

1. Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics—2014 update: A report from the American Heart Association. Circulation 2014;129:e28–e292.
2. Vital signs: Awareness and treatment of uncontrolled hypertension among adults–United States, 2003-2010.MMWRMorbMortal Wkly Rep 2012;61:703–709.
3. Rosei EA, Muiesan ML, Rizzoni D. Cardiac and vascular alterations in resistant hypertension. In: ManciaG, ed. Resistant Hypertension: Epidemiology, Pathophysiology, Diagnosis and Treatment. Milan, Italy: Springer-Verlag Italia, 2013:39–50.
4. Mellen PB, Herrington DM. Pharmacogenomics of blood pressure response to antihypertensive treatment. J Hypertens 2005;23: 1311–1325.
5. Gong Y, McDonough CW, Padmanabhan S et al. Hypertension pharmacogenomics. In: Padmanabhan S, ed. Handbook of Pharmacogenomics and Stratified Medicine. London, U.K.: Academic Press, 2014:747–778.
6. Johnson JA. Advancing management of hypertension through pharmacogenomics. Ann Med 2012;44(suppl 1):S17–S22.
7. Newton-Cheh C, Johnson T, Gateva V et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009;41:666–676.
8. Levy D, Ehret GB, Rice K et al. Genomewide association study of blood pressure and hypertension. Nat Genet 2009;41: 677–687.
9. Turner ST, Boerwinkle E, O’Connell JR et al. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension 2013;62: 391–397.
10. Johnson JA, Boerwinkle E, Zineh I et al. Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 2009;157:442–449.
11. Turner ST, Bailey KR, Schwartz GL et al. Genomicassociation analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension 2012;59:1204–1211.
12. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663–676.
13. Hankowski KE, Hamazaki T, Umezawa A et al. Induced pluripotent stem cells as a nextgeneration biomedical interface. Lab Invest 2011;91:972–977.
14. Zhu H, Lensch MW, Cahan P et al. Investigating monogenic and complex diseases with pluripotent stem cells. Nat Rev Genet 2011;12: 266–275.
15. Santostefano KE, Hamazaki T, Biel NM et al. A practical guide to induced pluripotent stem cell research using patient samples. Lab Invest 2015;95:4–13.
16. Adams WJ, García-Cardeña G. Novel stem cell-based drug discovery platforms for cardiovascular disease. J Biomol Screen 2012; 17:1117–1127.
17. Braam SR, Tertoolen L, van de Stolpe A et al. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res (Amst) 2010;4: 107–116.
18. Moretti A, Bellin M, Welling A et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010;363:1397–1409.
19. Zhi D, Irvin MR, Gu CC et al. Wholeexome sequencing and an iPSC-derived cardiomyocyte model provides a powerful platform for gene discovery in left ventricular hypertrophy. Front Genet 2012;3:92.
20. Lan F, Lee AS, Liang P et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013;12:101–113.
21. Nishimura K, Sano M, Ohtaka M et al. Development of defective and persistent Sendai virus vector: A unique gene delivery/ expression system ideal for cell reprogramming. J Biol Chem 2011;286:4760–4771.
22. Ross JJ, Hong Z, Willenbring B et al. Cytokine-induced differentiation of multipotent adult progenitor cells into functional smooth muscle cells. J Clin Invest 2006;116: 3139–3149.
23. Marchand M, Anderson EK, Phadnis SM et al. Concurrent generation of functional smooth muscle and endothelial cells via a vascular progenitor. STEM CELLS TRANSLATIONAL MEDICINE 2014;3:91–97.
24. Bajpai VK, Mistriotis P, Loh YH et al. Functional vascular smooth muscle cells derived from human induced pluripotent stem cells viamesenchymal stemcell intermediates. Cardiovasc Res 2012;96:391–400.
25. Rufaihah AJ, Huang NF, Kim J et al. Human induced pluripotent stem cell-derived endothelial cells exhibit functional heterogeneity. Am J Transl Res 2013;5:21–35.
26. Simmons CS, Ribeiro AJ, Pruitt BL. Formation of composite polyacrylamide and silicone substrates for independent control of stiffness and strain. Lab Chip 2013;13:646–649.
27. Thielicke W, Stamhuis EJ. PIVlab – towards user-friendly, affordable and accurate digital particle image velocimetry in MATLAB. J Open Res Softw 2014;2:e30.
28. Mierke CT, Kollmannsberger P, Zitterbart DP et al. Mechano-coupling and regulation of contractility by the vinculin tail domain. Biophys J 2008;94:661–670.
29. Sabass B, Gardel ML, WatermanCMet al. High resolution traction force microscopy based on experimental and computational advances. Biophys J 2008;94:207–220.
30. Xia G, Gao Y, Jin S et al. Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 iPS-cell derived neural stem cells. STEM CELLS 2015; 33:1829–1838.
31. Wang CH, Lee YS, Lin SJ et al. Surface markers of heterogeneous peripheral blood-derived smooth muscle progenitor cells. Arterioscler Thromb Vasc Biol 2012; 32:1875–1883.
32. Harrison DG, Vinh A, Lob H et al. Role of the adaptive immune system in hypertension. Curr Opin Pharmacol 2010;10:203–207.
33. Butoi ED, Gan AM, Manduteanu I et al. Cross talk between smooth muscle cells and monocytes/activated monocytes via CX3CL1/CX3CR1 axis augments expression of proatherogenicmolecules. Biochim Biophys Acta 2011;1813:2026–2035.
34. Liu H, Jiang D. Fractalkine/CX3CR1 and atherosclerosis. Clin Chim Acta 2011;412: 1180–1186.
35. Cybulsky MI, Hegele RA. The fractalkine receptor CX3CR1 is a key mediator of atherogenesis. J Clin Invest 2003;111:1118–1120.
36. Sone M, Itoh H, Yamahara K et al. Pathway for differentiation of human embryonic stem cells to vascular cell components and their potential for vascular regeneration. Arterioscler Thromb Vasc Biol 2007;27: 2127–2134.
37. Taura D, SoneM, Homma K et al. Induction and isolation of vascular cells from human induced pluripotent stem cells–brief report. Arterioscler Thromb Vasc Biol 2009; 29:1100–1103.
38. Park SW, Jun Koh Y, Jeon J et al. Efficient differentiation of human pluripotent stem cells into functional CD34+ progenitor cells by combined modulation of the MEK/ERK and BMP4 signaling pathways. Blood 2010; 116:5762–5772.
39. Lee TH, Song SH, Kim KL et al. Functional recapitulation of smooth muscle cells via induced pluripotent stem cells from human aortic smooth muscle cells. Circ Res 2010;106: 120–128.
40. Xie C, Hu J, Ma H et al. Three-dimensional growth of iPS cell-derived smooth muscle cells on nanofibrous scaffolds. Biomaterials 2011; 32:4369–4375.
41. Marchand A, Abi-Gerges A, Saliba Y et al. Calcium signaling in vascular smooth muscle cells: From physiology to pathology. In: Islam S, ed. Calcium Signaling: Advances in Experimental Medicine and Biology. Dordrecht, The Netherlands: Springer Science+Business Media; 2012:795–810.
42. Salamanca DA, Khalil RA. Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in hypertension. Biochem Pharmacol 2005;70:1537–1547.
43. Kamm KE, Stull JT. The function of myosin and myosin light chain kinase phosphorylation in smooth muscle. Annu Rev Pharmacol Toxicol 1985;25:593–620.
44. Mih JD, Sharif AS, Liu F et al. A multiwall platform for studying stiffness-dependent cell biology. PLoS One 2011;6:e19929.